Clinical trial · Interventional
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
NCT03764137CI-TRIAL-00085347PanitumumabwithdrawnPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was not able to enroll any subjects
Summary
Brief summary (as posted)
This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colon Cancer | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [89Zr]Panitumumab PET-MRI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [89Zr]Panitumumab-PET/MRI patients
- description
- All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.
- interventionNames
- Drug: [89Zr]Panitumumab PET-MRI
Primary outcomes (1)
- measure
- Image Quality
- timeFrame
- 12 months
- description
- Diagnostic image quality of \[89Zr\]Panitumumab PET imaging in patients with newly diagnosed colon cancer with nodal involvement. Standardized Uptake Values (SUVs) will be measured.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Be at least 19 years of age. * Diagnosis of colon cancer * Scheduled to undergo surgical resection Exclusion Criteria: * Inability to provide informed consent * Pregnancy * Inability to lie still for the imaging study * Weight over 350 lbs., due to the scanner bore size * Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) * Inability to receive Omnipaque (iohexol) iodinated contrast * Inability to receive glucagon * Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent * Allergy to contrast imaging agents * Finding or suspicion of distant metastases on CT
References
Publications (0)
Data not yet available
No reference posted for this study.